Longitudinal trajectories of hematological indices and serum metalloproteinases-2 and 9 over 1 year after moderate and severe COVID-19 - Scorecard - MDSpire

Longitudinal trajectories of hematological indices and serum metalloproteinases-2 and 9 over 1 year after moderate and severe COVID-19

  • By

  • Rebecca Salomão

  • Gabriel Pasquarelli-do-Nascimento

  • Mayara Ananias

  • Victoria Assis

  • Leandro Gomes de Jesus Ferreira

  • Isabella da Silva Almeida

  • Leandra Silva

  • Katiane Tostes

  • Bruna Pereira Sorroche

  • Lidia Maria Rebolho Batista Arantes

  • Kelly Grace Magalhães

  • Liliana Torcoroma García

  • Rochelle Rocha Costa

  • João Luiz Quagliotti Durigan

  • Rita de Cássia Marqueti

  • June 12, 2026

  • 0 min

Share

Clinical Scorecard: Year-long Analysis of Hematological Parameters and Serum Metalloproteinases-2 and 9 Following Moderate to Severe COVID-19

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationAdults aged 18–80 years with moderate or severe COVID-19, including non-COVID-19 controls.
Care Setting

Key Highlights

  • Renal function tests and hepatic enzymes remained stable across groups.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Biomarker panels may inform future studies on post-acute risk stratification and guide treatment decisions.

          Clinical Best Practices

          • Utilize blood-based biomarkers for monitoring long-term sequelae of COVID-19.
          • Evaluate hematological parameters regularly in patients with a history of severe COVID-19 and ensure follow-ups to monitor changes.

          Related Resources & Content

          Original Source(s)

          Longitudinal trajectories of hematological indices and serum metalloproteinases-2 and 9 over 1 year after moderate and severe COVID-19

          • by Rebecca Salomão, Gabriel Pasquarelli-do-Nascimento, Mayara Ananias, Victoria Assis, Leandro Gomes de Jesus Ferreira, Isabella da Silva Almeida, Leandra Silva, Katiane Tostes, Bruna Pereira Sorroche, Lidia Maria Rebolho Batista Arantes, Kelly Grace Magalhães, Liliana Torcoroma García, Rochelle Rocha Costa, João Luiz Quagliotti Durigan, Rita de Cássia Marqueti

          • June 12, 2026

          Related Content

          FDA Monthly Preview: Key June Decisions to Watch

          Several FDA decisions across multiple specialties are expected this month.

          How long Covid’s scientific stalemate made it politically erasable

          When Bad Data Enters the Drug Pipeline

          Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.